. Author manuscript; available in PMC: 2019 Nov 17.

Published in final edited form as: Cancer Metastasis Rev. 2016 Jun;35(2):333–346. doi: 10.1007/s10555-016-9622-4

Table 1.

Therapeutic drugs for bone metastatic environments: shared treatments for the bone metastatic niche

Cancer type	Drug	References
Prostate	Zoledronic acid, denosumab	[89]
Breast	Zoledronic acid, denosumab	[90]
Lung	Zoledronic acid, denosumab	[91]
Other solid tumors (renal/bladder/thyroid/liver/gastric/colorectal)	Zoledronic acid, denosumab	[92-97]

The current treatment options for bone tumor microenvironment are uniform and similar across cancer types. Zoledronic acid, a specific apoptosis inducer of osteoclasts, and denosumab (anti-RANKL antibody), a suppresser for osteoclast differentiation, are effective and recommended regardless of cancer cells’ origin